Repurposed Drugs

I’m going to be brutally honest with you: 95 to 98 percent of these are going to fail. But we only need one or two - Sumit K. Chanda PhD

Repurposed Drugs

image by: 楊承勳

Resources

RECOVERY Trial

This international clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19

Can Drugs for Other Diseases Help People With Mild or Moderate COVID-19?

The National Institutes of Health (NIH) is launching new trials to see if medications already in pharmacies can be repurposed to help people with mild or moderate COVID-19. Here’s a look, plus info on how to volunteer from the comfort of your couch.

Ivermectin shows us how hard it is to use old drugs for COVID. Here’s how to do better next time

Many hopes have been pinned on repurposing existing drugs, such as ivermectin and hydroxychloroquine, to treat COVID-19. However, we shouldn’t be too surprised these drugs haven’t yet lived up to the hype. Our study, published today in Science Translational Medicine, shows it’s notoriously difficult to repurpose existing drugs for new diseases or for new uses. Here’s what we need to consider for this pandemic — and the next.

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

Repurposed drugs tested to fight COVID-19 have been chosen mainly on the basis of promising in vitro efficacy against SARS-CoV-2 or on previous therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (1).

No stone unturned: fighting Covid-19 with repurposed drugs

A number of trials worldwide are seeking to identify repurposed treatments that could be beneficial for Covid-19 patients.

Repurposing drugs can speed new treatments for Covid-19

Repurposing drugs has immense benefits for both developers and consumers. Risks are greatly reduced, as the drugs have not only gone through safety trials but have been widely used. The availability of safety data shortens the timeline to approval. The need for fewer trials over less time translates into lower development costs. Rising vaccination rates are one step toward beating the coronavirus. But focusing on versatile, already-approved treatments could dramatically increase the speed with which we are able to defeat Covid, while also saving money.

The antivirals that weren’t: drug repurposing for COVID-19 produced misleading results

A common class of compounds disrupts the cell rather than stops the virus. A large, multi-institutional team led by Nevan J. Krogan, Kevan M. Shokat, and Brian K. Shoichet from the University of California, San Francisco, tested 23 repurposed cationic amphiphilic drugs (CADs), including hydroxychloroquine, amiodarone, and sertraline. The researchers found that what looked like antiviral activity in cells was actually the result of a mechanism called phospholipidosis, which disrupts cells by interrupting fundamental cellular processes.

The King of AIDS Treatments Is Turning to COVID-19

There are few drugs proven to help people infected with the coronavirus, and it’s giving John James déjà vu.

Investigate Good, Existing Covid Therapies

Sen. Johnson has written to agencies asking what resources were devoted to exploring repurposed drugs. This has yielded little to no response, leading us to assume those agencies have done little to no such research. This must change.

Is drug repurposing worth the effort?

What the pandemic has shown us about how to redeploy our pharmaceutical arsenal

Old Drugs May Find a New Purpose: Fighting the Coronavirus

A “drug repurposing” strategy uncovers dozens of compounds that have the unexpected potential to combat the virus.

Rapid repurposing of drugs for COVID-19

One approach to identifying therapeutics is to repurpose approved drugs developed for other uses, which takes advantage of existing detailed information on human pharmacology and toxicology to enable rapid clinical trials and regulatory review.

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.

Repurposing Drugs Is Key To Fighting The Coronavirus Pandemic, This Virologist Explains

Drug repurposing for combatting infectious diseases has become a critically important area of biomedical research, and presents a potentially fruitful area for combatting growing global health problems. But even as we search for the fastest way to find a cure for this pandemic and future diseases, we still cannot lose sight of the importance of conducting carefully controlled studies for evaluating new drugs.